BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112.

@article{Muers2004BTSRF,
  title={BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112.},
  author={M. Thirumaran M. F. Muers and Robin Michael Rudd and Mary R O'Brien and W Qian and Ann Hodson and Mahesh K B Parmar and David J Girling},
  journal={Thorax},
  year={2004},
  volume={59 2},
  pages={144-8}
}
BACKGROUND The incidence of mesothelioma is rising rapidly in the UK. There is no generally accepted standard treatment. The BTS recommends active symptom control (ASC). It is not known whether chemotherapy in addition prolongs survival or provides worthwhile palliation with acceptable toxicity. Palliation as recorded by patients has been fully reported for only two regimens: mitomycin, vinblastine, and cisplatin (MVP), and vinorelbine (N). The BTS and collaborators planned to conduct a phase… CONTINUE READING
10 Citations
9 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

References

Publications referenced by this paper.
Showing 1-9 of 9 references

Phase II study of vinorelbine in patients with malignant pleural mesothelioma

  • PG Sorensen, F Bach, E Bork
  • J Clin Oncol
  • 2000

Phase III single - blinded study of pemetrexed + cisplatin vs . cisplatin alone in chemonaive patients with malignant pleural mesothelioma

  • NJ Vogelzang, J Rusthoven, P Paoletti
  • Br J Cancer
  • 1999

A review of chemotherapy trials for malignant mesothelioma

  • GW Middleton, IE Smith, O’Brien MER
  • Chest
  • 1998

Randomised trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma

  • MK Samson, LP Wasser, EC Borden
  • Cancer Treat Rep
  • 1985

Similar Papers

Loading similar papers…